HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche vitamins deal

This article was originally published in The Rose Sheet

Executive Summary

DSM signs contract to acquire Roche's vitamins, carotenoids and fine chemicals business for €300 mil. less than originally announced, firms say Feb. 10. The roughly $2.24 bil. price tag agreed upon in September has been lowered due to "the continued slow-down of the world's economies and the weakening" of the U.S. dollar versus the Swiss Franc, "which both had a negative impact on the vitamin business performance compared to earlier forecasts," firms say (1"The Rose Sheet" Sept. 9, 2002, p. 3). As a result, DSM will pay about $2.09 bil. (€1=$1.07). Roche will take an impairment charge of $1.2 bil. in its 2002 results, and also will increase its provisions for liabilities relating to vitamin price-fixing charges. Still subject to approval by anti-trust authorities, the transaction is slated to close in spring...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS010979

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel